In: Clinical Infectious Diseases, 1993, vol. 17, no. 1, p. 59-65
|
In: Journal of Infectious Diseases, 2011, vol. 203, no. 2, p. 246-257
|
In: The Journal of Infectious Diseases, 2010, vol. 201, no. 10, p. 1488-1497
|
In: Journal of Antimicrobial Chemotherapy, 2007, vol. 59, no. 5, p. 1034-1037
|
In: Clinical Infectious Diseases, 1995, vol. 20, no. 4, p. 772-775
|
In: Clinical Infectious Diseases, 1994, vol. 18, no. 3, p. 455-457
|
In: Journal of Infectious Diseases, 2008, vol. 197, no. 12, p. 1685-1694
|
In: Clinical Infectious Diseases, 2007, vol. 45, no. 1, p. 111-119
|
In: Clinical Infectious Diseases, 2010, vol. 50, no. 1, p. 115-118
|
In: Neurology, 2013, vol. 80, no. 6, p. 553–560
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by placebo...
|